Findings

What do systematic reviews say?

6 questions · 6 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 1 · 16.7%GRADE not reported 0 · 0%Very low 4 · 66.7%Low 1 · 16.7%Moderate 0 · 0%High 0 · 0%

Tafamidis vs placebo

Disability due to FAP progression Not measured · people with early‐stage TTR‐FAP

The review found no eligible studies for this question.

1 finding from 1 review

Pharmacological treatment for familial amyloid polyneuropathy 2020 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Tafamidis vs placebo

Severity of peripheral neuropathy (expressed as the change in NIS‐LL) Scale from: 0 (normal) to 88 (total impairment) · people with early‐stage TTR‐FAP

1 finding from 1 review

Pharmacological treatment for familial amyloid polyneuropathy 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 125 participants
Low

Tafamidis vs placebo

QoL · people with early‐stage TTR‐FAP

1 finding from 1 review

Pharmacological treatment for familial amyloid polyneuropathy 2020 · Cochrane Headline outcomes only
no estimate extracted
1 study · 125 participants
Very low

Tafamidis vs placebo

Has died · people with early‐stage TTR‐FAP

It is very uncertain whether tafamidis changes number of participants who died during the trial compared with placebo (very low certainty).

1 finding from 1 review

Pharmacological treatment for familial amyloid polyneuropathy 2020 · Cochrane Headline outcomes only
RR 0.65 [0.11, 3.74]
1 study · 128 participants
Very low

Tafamidis vs placebo

Withdrawals due to adverse events · people with early‐stage TTR‐FAP

It is very uncertain whether tafamidis changes number of dropouts due to adverse events compared with placebo (very low certainty).

1 finding from 1 review

Pharmacological treatment for familial amyloid polyneuropathy 2020 · Cochrane Headline outcomes only
RR 1.29 [0.3, 5.54]
1 study · 128 participants
Very low

Tafamidis vs placebo

Number of participants experiencing at least one severe adverse event · people with early‐stage TTR‐FAP

It is very uncertain whether tafamidis changes number of participants experiencing at least one severe adverse event compared with placebo (very low certainty).

1 finding from 1 review

Pharmacological treatment for familial amyloid polyneuropathy 2020 · Cochrane Headline outcomes only
RR 1.16 [0.37, 3.62]
1 study · 128 participants
Very low